Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

T-cell therapies

Share :

ASH 2009

3 Dec 2011
Published: 27 Jan 2010
Views: 10725
Rating:
Save
Dr Catherine Bollard - Baylor College of Medicine, Texas, USA
Dr Catherine Bollard discusses novel T-cell therapies and the work of her laboratory.

Related Videos

Haematology malignancies and cellular therapy
Dr Hugo Fernandez - Moffitt Cancer Center, Tampa, USA
Haematology malignancies and cellular therapy ( Dr Hugo Fernandez - Moffitt Cancer Center, Tampa, USA )
8 Jul 2023
Hodgkin’s and non-Hodgkin’s lymphomas (NHL)
Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA
Hodgkin’s and non-Hodgkin’s lymphomas (NHL) ( Dr Jose Sandoval Sus - Memorial Healthcare System, Florida, USA )
8 Jul 2023
Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone...
Prof Meletios Dimopoulos - National and Kapodistrian University of Athens...
Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )
15 Jun 2023
Triplets for newly diagnosed unfit AML patients could be feasible with...
Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain
Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction ( Dr Juan Miguel Bergua Burgues - Hospital San Pedro de Alcántara, Cáceres, Spain )
15 Jun 2023
Consolidation therapy with blinatumomab improves OS in newly diagnosed patients...
Dr Mark Litzow - Mayo Clinic, Rochester, USA
Consolidation therapy with blinatumomab improves OS in newly diagnosed patients with B-Lineage ALL in MRD negative remission ( Dr Mark Litzow - Mayo Clinic, Rochester, USA )
19 Dec 2022
PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning
Dr Shernan Holtan - University of Minnesota, Minneapolis, USA
PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning ( Dr Shernan Holtan - University of Minnesota, Minneapolis, USA )
15 Dec 2022
Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable...
Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA
Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )
12 Dec 2022
Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable...
Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA
Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in R/R follicular lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )
12 Dec 2022
Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly...
Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain
Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly with relapsed/refractory large B-cell lymphoma ( Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain )
1 Jul 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation